| Literature DB >> 27115008 |
Hao Lu1, Ling Lu1, Feng Zhang1, Yuan Zhai1, Xuehao Wang1.
Abstract
Liver transplantation (LT) remains a lifesaving therapy for patients with end-stage liver disease, but the shortage of graft donor (deceased donor) limits development of LT. Living donor liver transplantation (LDLT) is the only alternative to deceased donor liver transplantation (DDLT), but LDLT requires more sophisticated surgical techniques. In addition, LDLT does not have the advantage in their survival in response to immunosuppressive therapies. In this paper, we reviewed recent development of LDLT in China mainland, especially surgical technique and immune therapy.Entities:
Keywords: Living donor liver transplantation (LDLT); immune therapy; regulatory T cells (Tregs); small-for-size syndrome (SFSS)
Year: 2016 PMID: 27115008 PMCID: PMC4824740 DOI: 10.3978/j.issn.2304-3881.2015.10.02
Source DB: PubMed Journal: Hepatobiliary Surg Nutr ISSN: 2304-3881 Impact factor: 7.293